# US 2022/0275334 A1 · Nk cell compositions and preparations for immunotherapy and methods for their production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0275334 A1
- Document ID: US20220275334A1
- Status: Published application
- Kind: A1
- Application number: 17/631,035
- Filed: 2020-07-29
- Published: 2022-09-01
- Earliest claimed: 2019-07-29
- Assignees: Deverra Therpaeutics Inc.
- Applicants: Deverra Therapeutics Inc.
- Inventors: Colleen Delaney; Carrie Stoltzman; Elizabeth Dam; Mary Prieve
- Web page: https://patentgrep.com/patent/US20220275334A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4255: {Mesothelin [MSLN]}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/47: Brain; Nervous system
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2500/84: from mammals
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/145: Thrombopoietin [TPO]
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2303: Interleukin-3 (IL-3)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/26: Flt-3 ligand (CD135L, flk-2 ligand)
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2502/115: Platelets, megakaryocytes
- C12N 2506/03: from non-embryonic pluripotent stem cells
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides NK cell compositions and/or preparations and methods of using such NK cell compositions and/or preparations for immunotherapy. The NK cell compositions and/or preparations can be used in therapies of a broad range of viral infections, bacterial infections, cancer and leukemia malignancies, and other diseases.

## Claims

### Claim 1

A method of preparing a natural killer (NK) cell preparation for use in immunotherapy, comprising:
selecting a plurality of umbilical cord blood or placental blood cells without immunological matching to each other;
preparing enriched CD34+ hematopoietic stem and progenitor cells (HSPCs) that are depleted of red blood cells and T cells;
culturing the CD34+ enriched HSPCs in an expansion culture medium comprising interleukin-3 (IL-3), interleukin-6 (IL-6), thrombopoietin (TPO), Flt-3 ligand (Flt-3L), and stem cell factor (SCF) on a solid phase coated with a Notch ligand and recombinant human fibronectin or fragments thereof, and in the absence of exogenous feeder cells, for a sufficient time to produce expanded HSPCs, wherein the expanded HSPCs do not substantially differentiate into CD56+ cells during the expansion; and
culturing the expanded HSPCs in a differentiation culture medium comprising effective amounts of IL-2 and IL-15, a non-animal sourced serum replacement, and in the absence of the exogenous feeder cells for a sufficient time to produce an NK cell composition and/or preparation comprising about 50 to about 80% CD56+ cells and about 50 to about 20% endogenous CD56− cells, or about 50 to about 85% CD56+ cells and about 50 to about 15% endogenous CD56− cells;
wherein the CD56+ cells express a high frequency of NKp30, NKp46, NKp44, NKG2A, and granzyme B, a moderate to high frequency of perforin and CD107a, a low to moderate frequency of CD16, and substantially no KIRs; and wherein the CD56− cells express a moderate to high frequency of granzyme B, a high frequency of CD107a, and a low frequency of perforin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the expansion culture medium does not contain exogenous IL-15, IL-7, IL-2, G-CSF, GM-CSF, LIF, MIP-1a, or an aryl hydrocarbon receptor antagonist.

### Claim 3 (depends on 1)

The method of claim 1, wherein IL-15 is added during the expansion of the CD34+ enriched HSPCs.

### Claim 4 (depends on 3)

The method of claim 3, wherein the IL-15 is added during the last about 4 to 7 days of the expansion phase.

### Claim 5

The method of any of the preceding claims, wherein the differentiation culture medium does not contain added Flt-3L, FGF-2, IL-6, IL-7, IL-12, IL-3, GM-CSF, G-CSF, LIF, MIP-1alpha, SCF, IL-21, IL-18, and 4-1BBL.

### Claim 6

The method of any of the preceding claims, wherein IL-2 and IL-15 are the only added cytokines to the differentiation culture medium.

### Claim 7

The method of any of the preceding claims, wherein the differentiation culture medium does not contain exogenous antigen presenting cells.

### Claim 8

The method of any of the preceding claims, wherein the non-animal serum replacement is human AB serum, fresh frozen human plasma, or human platelet lysate.

### Claim 9

The method of any of the preceding claims, wherein the HSPCs are not derived from somatic cells, embryonic stem cells, peripheral blood mononuclear cells or induced pluripotent stem cells.

### Claim 10

The method of any of the preceding claims, wherein the NK cell composition and/or preparation comprises less than 2% CD3+ cells, less than 2% CD19+ cells, and/or less than 2% CD34+ cells.

### Claim 11

The method of any of the preceding claims, wherein the CD56+ cells further express a high frequency of KIR2DL4.

### Claim 12

The method of any of the preceding claims, wherein the Notch ligand is DXI or an antibody specific for Notch.

### Claim 13

The method of any of the preceding claims, wherein cells of the NK cell composition and/or preparation are genetically modified.

### Claim 14 (depends on 13)

The method of claim 13, wherein the genetic modification is during the expansion phase or subsequent to differentiation of the NK cells.

### Claim 15 (depends on 13, 14)

The method of any one of claim 13 or 14, wherein the cells of the NK cell composition and/or preparation are genetically modified to express an antigen recognizing receptor.

### Claim 16 (depends on 13, 14, 15)

The method of any one of claims 13 to 15, wherein the genetic modification is introduction of a polynucleotide expressing a TCR or a CAR.

### Claim 17 (depends on 16)

The method of claim 16, wherein the TCR or the CAR specifically binds to a viral antigen, a bacterial antigen, a tumor specific, or tumor associated antigen.

### Claim 18 (depends on 17)

The method of claim 17, wherein the viral antigen is present in a Cytomegalovirus (CMV), an Epstein Barr Virus (EBV), a Human Immunodeficiency Virus (HIV), a Herpes simplex virus (HSV), a Hepatitis virus, a zika virus, an influenza virus, or a coronavirus.

### Claim 19 (depends on 18)

The method of claim 18, wherein the Herpes virus is HSV 1 or HSV 2, the Hepatitis virus is Hepatitis A, B, or C, and the coronavirus is SARS-CoV or SARS-CoV-2.

### Claim 20 (depends on 17)

The method of claim 17, wherein the tumor specific or tumor associated antigen is carbonic anhydrase IX (CA1X), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, an antigen of a cytomegalovirus (CMV) infected cell (e.g., a cell surface antigen), cutaneous lymphocyte-associated antigen (CLA; a specialized glycoform of P-selectin glycoprotein ligand-1 (PSGL-1)), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine-protein kinases erb-B2,3,4 (erb-B2,3,4), folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-alpha, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Growth Factor Receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), Interleukin-13 receptor subunit alpha-2 (IL-13Ralpha2), kappa-light chain, kinase insert domain receptor (KDR), Lewis Y (LeY), L1 cell adhesion molecule (L1CAM), melanoma antigen family A, 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGEA3, p53, MART1, GP100, Proteinase3 (PR1), Tyrosinase, Survivin, hTERT, EphA2, an NKG2D ligand, cancer-testis antigen NY-ES0-1, oncofetal antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspanin 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), Wilms tumor protein (WT-1), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, CRLF2, or ERBB

### Claim 21 (depends on 20)

The method of claim 20, wherein the tumor specific or tumor associated antigen is CD19, ROR1, Her2, PSMA, PSCA, mesothelin, or CD20.

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

The method of any of claims 16 to 21, wherein the CAR further comprises an intracellular signaling domain comprising a signaling domain of CD3zeta, CD28, and 4-1BB; at least one co-stimulatory domain comprising a co-stimulatory domain of CD27, CD28, 4-1BB, 2B4, DAP10, DAP12, OX40, CD30, CD40, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, or B7-H3; a transmembrane domain comprising a transmembrane domain of CD8, CD28, CD3zeta, CD4, 4-1BB, OX40, ICOS, or NKG2D; and a spacer region comprising a hinge region of IgG1, the CH2CH3 region of an immunoglobulin, a portion of CD3, a portion of CD28, or a portion of CD8.

### Claim 23 (depends on 22)

The method of claim 22, wherein the CAR comprises a single chain Fv (scFv) having the CDRs of monoclonal antibody FMC63.

### Claim 24

The method of any of the preceding claims, wherein the NK cell composition and/or preparation further comprises a cryoprotective agent.

### Claim 25

The method of any of the preceding claims, further comprising formulating the NK cell preparation to form a NK cell composition for infusion into a subject.

### Claim 26

A natural killer (NK) cell composition for use in immunotherapy, comprising:
about 50 to about 80% CD56+ cells and about 50 to about 20% endogenous CD56− cells, or about 50 to about 85% CD56+ cells and about 50 to about 15% endogenous CD56− cells, wherein the CD56+ cells express a high frequency of NKp30, NKp46, NKp44, NKG2A, NKG2D, and granzyme B, a moderate to high frequency of perforin and CD107a, a low to moderate frequency of CD16 and substantially no KIRs; and wherein the CD56− cells express a moderate to high frequency of granzyme B, a high frequency of CD107a, and a low frequency of perforin, and a pharmaceutically acceptable carrier.

### Claim 27 (depends on 26)

The NK cell composition of claim 26, wherein the preparation does not contain exogenous feeder cells.

### Claim 28 (depends on 26, 27)

The NK cell composition of any of claims 26 to 27, wherein the NK cell composition is produced from Notch ligand-expanded HSPCs.

### Claim 29 (depends on 26, 27, 28)

The NK cell composition of any one of claims 26 to 28, wherein the NK cell composition comprises less than 2% CD3+ cells, less than 2% CD19+ cells, and/or less than 2% CD34+ cells.

### Claim 30 (depends on 26, 27, 28, 29)

The NK cell composition of any one of claims 26 to 29, wherein the CD56+ cells further express a high frequency of KIR2DL4.

### Claim 31 (depends on 26, 27, 28, 29, 30)

The NK cell composition of any one of claims 26 to 30, wherein the cells of the composition are genetically modified.

### Claim 32 (depends on 31)

The NK cell composition of claim 31, wherein the cells of the composition are genetically modified to express an antigen recognizing receptor.

### Claim 33 (depends on 31, 32)

The NK cell composition of any one of claims 31 to 32, wherein the genetic modification comprises introduction of a polynucleotide expressing a TCR or a CAR.

### Claim 34 (depends on 33)

The NK cell composition and/or preparation of claim 33, wherein the TCR or the CAR specifically binds to a viral antigen, a bacterial antigen, or a tumor associated or tumor specific antigen.

### Claim 35 (depends on 34)

The NK cell composition and/or preparation of claim 34, wherein the viral antigen is present in a Cytomegalovirus (CMV), an Epstein Barr Virus (EBV), a Human Immunodeficiency Virus (HIV), a Herpes simplex virus (HSV), a Hepatitis virus, a zika virus, an influenza virus, or a coronavirus.

### Claim 36 (depends on 35)

The NK cell composition and/or preparation of claim 35, wherein the Herpes virus is HSV 1 or HSV 2, the Hepatitis virus is Hepatitis A, B or C, or the coronavirus is SARS-CoV or SARS-CoV-2.

### Claim 37 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34)

The NK cell composition and/or preparation of any one of claims 26 to 34, wherein the tumor associated or tumor specific antigen is carbonic anhydrase IX (CA1X), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, an antigen of a cytomegalovirus (CMV) infected cell (e.g., a cell surface antigen), cutaneous lymphocyte-associated antigen (CLA; a specialized glycoform of P-selectin glycoprotein ligand-1 (PSGL-1)), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine-protein kinases erb-B2,3,4 (erb-B2,3,4), folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-alpha, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Growth Factor Receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), Interleukin-13 receptor subunit alpha-2 (IL-13Ralpha2), kappa-light chain, kinase insert domain receptor (KDR), Lewis Y (LeY), L1 cell adhesion molecule (L1CAM), melanoma antigen family A, melanoma-associated antigen A1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGEA3, p53, MART1, GP100, Proteinase3 (PR1), tyrosinase, Survivin, hTERT, EphA2, an NKG2D ligand, cancer-testis antigen NY-ES0-1, oncofetal antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspanin 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), Wilms tumor protein (WT-1), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, CRLF2, or ERBB.

### Claim 38 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The NK cell composition of any one of claims 26 to 37, wherein the tumor associated or tumor specific antigen is CD19, ROR1, Her2, PSMA, PSCA, mesothelin, CRLF2, or CD20.

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

The NK cell composition of any one of claims 33 to 38, wherein the antigen recognizing receptor is a CAR.

### Claim 40 (depends on 39)

The NK cell composition of claim 39, wherein the CAR comprises an intracellular signaling domain of CD3zeta, CD28, and 4-1BB; at least one co-stimulatory domain of CD27, CD28, 4-1BB, 2B4, DAP10, DAP12, OX40, CD30, CD40, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, or B7-H3 costimulatory domain; a transmembrane domain of CD8, CD28, CD3zeta, CD4, 4-1BB, OX40, ICOS, or NKG2D; and a spacer region of IgG1, the CH2CH3 region of an immunoglobulin, a portion of CD3, a portion of CD28, or a portion of CD8.

### Claim 41 (depends on 37, 38, 39, 40)

The NK cell composition of any of any one of claims 37 to 40, wherein the tumor antigen is CD19.

### Claim 42 (depends on 37, 38, 39, 40)

The NK cell composition of any one of claims 37 to 40, wherein the tumor associated or tumor specific antigen is HER2 or mesothelin.

### Claim 43 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The NK cell composition of any one of claims 26 to 42, further comprising a cryoprotective agent.

### Claim 44 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The NK cell composition of any one of claims 26 to 42, wherein the NK cell composition is formulated for infusion into a subject.

### Claim 45 (depends on 44)

The NK cell composition of claim 44, wherein the NK cell composition comprises from about 50 million to about 2 billion viable cells.

### Claim 46 (depends on 44)

The NK cell composition of claim 44, wherein the NK cell composition comprises from about 50 million to about 2 billion viable CD56+ cells.

### Claim 47 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A method of treating a subject in need thereof, comprising administering a therapeutically effective amount of the NK cell composition of any one of claims 26 to 46 to the subject.

### Claim 48 (depends on 47)

The method of claim 47, wherein the subject has a cancer expressing a tumor antigen and the NK cells of the composition express an antigen recognizing receptor that binds to the tumor antigen.

### Claim 49 (depends on 47)

The method of claim 47, wherein the subject has a viral or a bacterial infection and the NK cells of the composition express an antigen recognizing receptor that binds to the virus or bacteria.

### Claim 50 (depends on 26, 27, 28, 29, 30, 31, 47)

The method of claim 47, wherein the subject has a viral or a bacterial infection and the subject is administered the NK cell composition and/or preparation of any one of claims 26 to 31.

### Claim 51 (depends on 50)

The method of claim 50, wherein the NK cell composition comprises a cryoprotective agent.
